Veradermics, Incorporated
MANE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.84B
Close$
$0.62
99.6% downside
Current Fair Value
99.6% downsideOvervalued by 99.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.84 Billion |
|---|---|
| Enterprise Value | $5.52 Billion |
| Earnings per Share | $-2.38 |
| Beta | 1.23 |
| Outstanding Shares | 40,436,000 |
Return
| Return on Equity | -9.62% |
|---|---|
| Return on Assets | -9.48% |
| Return on Invested Capital | -10.78% |
Valuation & Multiples
| P/E Ratio | -50.25 |
|---|---|
| PEG | -15.94 |
| Price to Sales | - |
| Price to Book Ratio | 6.98 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -62.84 |
| Enterprise Value to Net Income | -71 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.67
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-0.59
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.09%▼ 84.27% |
|---|---|
| Total Invested | $4.52M▼ 99.89% |
| Investors Holding | 19▼ 147.00% |
About Veradermics, Incorporated
21 employees
CEO: Reid Waldman
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. Th...